Tumor necrosis factor‐alpha antibody for maintenance of remission in Crohn's disease

Background Crohn's disease may be refractory to conventional treatments including corticosteroids and immunosuppressives. Recent studies suggest TNF‐α blocking agents may be effective in maintaining remission in Crohn's disease. Objectives To conduct a systematic review of the evidence for...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cochrane database of systematic reviews 2008-01, Vol.2010 (1), p.CD006893-CD006893
Hauptverfasser:	Behm, Brian W, Bickston, Stephen J
Format:	Artikel
Sprache:	eng
Schlagworte:	Adalimumab Anti-Inflammatory Agents - therapeutic use Antibodies, Monoclonal Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Anti‐Inflammatory Agents Certolizumab Pegol Crohn Disease Crohn Disease - drug therapy CROHN'S DISEASE ‐ MAINTENANCE OF REMISSION Gastroenterology & hepatology Humans Immunoglobulin Fab Fragments Immunoglobulin Fab Fragments - therapeutic use Inflammatory bowel disease Infliximab Medicine General & Introductory Medical Sciences Polyethylene Glycols Polyethylene Glycols - therapeutic use Randomized Controlled Trials as Topic Remission Induction Tumor Necrosis Factor-alpha - antagonists & inhibitors Tumor Necrosis Factor‐alpha Tumor necrosis factor‐alpha therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!